Comparative Pharmacology
Head-to-head clinical analysis: QUARTETTE versus TRI PREVIFEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUARTETTE versus TRI PREVIFEM.
QUARTETTE vs TRI-PREVIFEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing drospirenone, ethinyl estradiol, levomefolate calcium, and metformin. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. Ethinyl estradiol is an estrogen. Levomefolate calcium is a folate supplement. Metformin is a biguanide that decreases hepatic glucose production and improves insulin sensitivity.
Combination oral contraceptive: ethinyl estradiol and norgestimate exert contraceptive effects primarily by suppression of gonadotropin secretion (FSH and LH), thereby inhibiting ovulation. Additionally, progestin induces changes in cervical mucus and endometrial receptivity.
3 mg orally once daily for 21 days followed by 7 days of placebo.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.025 mg) orally once daily for 21 days, followed by 7 days of placebo; repeat cycle.
None Documented
None Documented
Terminal elimination half-life is 12-14 hours; clinically this supports once-daily dosing with steady state achieved within 2-3 days.
Ethinyl estradiol: terminal half-life 13-27 hours; norgestimate: terminal half-life of norelgestromin (active metabolite) 12-30 hours; clinical context: once-daily dosing provides steady-state concentrations within 7-10 days.
Renal excretion accounts for 55% (primarily as unchanged drug), biliary/fecal excretion 35%, and the remainder undergoes metabolic clearance.
Ethinyl estradiol: 40% renal, 60% fecal; norgestimate and its metabolites: 80% renal, 20% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive